$80.28
3.31% yesterday
Nasdaq, Nov 25, 10:00 pm CET

Corcept Therapeutics Incorporated. Stock price

$80.28
+7.72 10.64% 1M
+1.59 2.02% 6M
+29.89 59.32% YTD
+21.25 36.00% 1Y
+54.18 207.59% 3Y
+57.45 251.64% 5Y
+75.03 1,429.14% 10Y
+75.81 1,695.97% 20Y
Nasdaq, Closing price Tue, Nov 25 2025
+2.57 3.31%

New AI Insights on Corcept Therapeutics Incorporated. Insights AI Insights on Corcept Therapeutics Incorporated.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$8.2b
Enterprise Value
$7.8b
Net debt
positive
Cash
$424.2m
Shares outstanding
105.1m
Valuation (TTM | estimate)
P/E
87.3 | 76.4
P/S
11.0 | 9.4
EV/Sales
10.5 | 8.9
EV/FCF
47.7
P/B
12.9
Financial Health
Equity Ratio
80.9%
Return on Equity
20.8%
ROCE
10.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$741.2m | $869.8m
EBITDA
$66.4m | $112.5m
EBIT
$65.6m | $117.6m
Net Income
$106.1m | $107.0m
Free Cash Flow
$162.6m
Growth (TTM | estimate)
Revenue
17.9% | 28.9%
EBITDA
-54.0% | -18.3%
EBIT
-54.3% | -14.1%
Net Income
-25.2% | -24.3%
Free Cash Flow
14.1%
Margin (TTM | estimate)
Gross
98.2%
EBITDA
9.0% | 12.9%
EBIT
8.9%
Net
14.3% | 12.3%
Free Cash Flow
21.9%
More
EPS
$0.9
FCF per Share
$1.5
Short interest
14.2%
Employees
500
Rev per Employee
$1.4m
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
90%
Hold
10%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
741 741
18% 18%
100%
- Direct Costs 13 13
37% 37%
2%
728 728
18% 18%
98%
- Selling and Administrative Expenses 402 402
65% 65%
54%
- Research and Development Expense 260 260
13% 13%
35%
66 66
54% 54%
9%
- Depreciation and Amortization 0.78 0.78
18% 18%
0%
EBIT (Operating Income) EBIT 66 66
54% 54%
9%
Net Profit 106 106
25% 25%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Neutral
Seeking Alpha
21 days ago
Corcept Therapeutics Incorporated ( CORT ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean Maduck - President of Endocrinology Joseph K. Belanoff - Co-Founder, President, CEO & Director William Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord Genuity ...
Neutral
Business Wire
21 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2025. Financial Results “The thir...
Neutral
Business Wire
28 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call...
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today